Imatinib-d 3 hydrochloride

Overview

Imatinib-d 3 (hydrochloride) is the deuterium labeled Imatinib. Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > SARS-CoV | Products > Signaling Pathways > c-Kit | Products > Signaling Pathways > Bcr-Abl | Products > Signaling Pathways > PDGFR

Product Information

• Catalog No.: HY-15463S2
• CAS No.: 1134803-18-1
• Molecular Formula: C29H28D3N7O
• Molecular Weight: 496.62
• Purity: 95.19%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source